Boston Scientific reports Q3 2026 results and cuts FY‑2026 outlook after cyberattack
+1 new source since this summary was written
Boston Scientific posted third‑quarter 2026 net sales of $5.138 billion, up 1.5% year‑over‑year, and adjusted EPS of $0.73. The company lowered its full‑year 2026 sales growth forecast to about 4.25% (reported) and adjusted EPS guidance to $3.16‑$3.18, citing the August cyber‑security incident that disrupted manufacturing and order processing. It also expects fourth‑quarter sales to decline 1%‑3% versus the prior year.
Why it matters
The reduced sales growth and earnings guidance signal lower near‑term earnings than analysts expected, which may pressure the stock price (the company’s shares fell 8%‑12% in pre‑market trading). The guidance also sets a new baseline for investors’ valuation models for the remainder of 2026.
Key facts
- 1Q3 2026 net sales were $5.138 billion, a 1.5% increase on a reported basis versus the prior year. prnewswire.com
- 2Adjusted EPS for Q3 2026 was $0.73 per share. prnewswire.com
- 3Full‑year 2026 net‑sales growth is now estimated at approximately 4.25% on a reported basis and 3.75% on an organic basis. prnewswire.com
- 4Adjusted EPS guidance for FY 2026 is $3.16 to $3.18 per share. prnewswire.com
- 5Q4 2026 net‑sales are expected to decline 1% to 3% versus the prior year. prnewswire.com
- 6The company attributes the weaker outlook to an August 2026 cyber‑attack that disrupted operations. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.